pentobarbital will reduce the extent or influence of cobimetinib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Keep away from coadministration. Potent or average CYP3A inducers could reduce cobimetinib systemic publicity by >80% and lower its efficacy. Barbiturat